CLINICAL TRIALS PROFILE FOR THIOTHIXENE HYDROCHLORIDE

All Clinical Trials for thiothixene hydrochloride

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01234454 ↗	Atypical Antipsychotic Treatment Effect On Brain Function In Schizophrenia Measured By FMRI	Completed	University of North Carolina, Chapel Hill	N/A	2002-01-01	The general aim is to compare the effects of typical and atypical antipsychotic medication on brain structure and function. A parallel group treatment trial will be utilized to compare the effects of the typical antipsychotic thiothixene versus the atypical antipsychotics risperidone (RIS) and olanzapine (OLZ) on brain structure and function in schizophrenia in an effort to determine the neuroanatomic basis for cognitive pathology in schizophrenia and its amelioration by atypical antipsychotic drugs.
NCT02582736 ↗	Antipsychotics and Risk of Hyperglycemic Emergencies	Completed	Canadian Institutes of Health Research (CIHR)		2012-04-01	The purpose of this study is to determine whether the use of atypical antipsychotic medication increases the risk of hospitalization for a hyperglycemic emergency. The investigators will carry out separate population-based cohort studies using administrative health databases in eight jurisdictions in Canada and the UK. Cohort entry will be defined by the initiation of a new antipsychotic medication. Follow-up will continue until hospitalization for a hyperglycemic emergency or the end of 365 days. The results from the separate sites will be combined to provide an overall assessment of the risk of hyperglycemic emergencies among new users of various antipsychotic drugs.
NCT02582736 ↗	Antipsychotics and Risk of Hyperglycemic Emergencies	Completed	Drug Safety and Effectiveness Network, Canada		2012-04-01	The purpose of this study is to determine whether the use of atypical antipsychotic medication increases the risk of hospitalization for a hyperglycemic emergency. The investigators will carry out separate population-based cohort studies using administrative health databases in eight jurisdictions in Canada and the UK. Cohort entry will be defined by the initiation of a new antipsychotic medication. Follow-up will continue until hospitalization for a hyperglycemic emergency or the end of 365 days. The results from the separate sites will be combined to provide an overall assessment of the risk of hyperglycemic emergencies among new users of various antipsychotic drugs.
NCT02582736 ↗	Antipsychotics and Risk of Hyperglycemic Emergencies	Completed	Canadian Network for Observational Drug Effect Studies, CNODES		2012-04-01	The purpose of this study is to determine whether the use of atypical antipsychotic medication increases the risk of hospitalization for a hyperglycemic emergency. The investigators will carry out separate population-based cohort studies using administrative health databases in eight jurisdictions in Canada and the UK. Cohort entry will be defined by the initiation of a new antipsychotic medication. Follow-up will continue until hospitalization for a hyperglycemic emergency or the end of 365 days. The results from the separate sites will be combined to provide an overall assessment of the risk of hyperglycemic emergencies among new users of various antipsychotic drugs.
NCT02600741 ↗	Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)	Completed	Janssen Scientific Affairs, LLC		2015-07-24	The primary purpose of this study is to evaluate the overall effect of caregivers receiving a study-provided caregiver psycho-education and skills training program on the number of treatment failures (psychiatric hospitalization, psychiatric emergency room (ER) visit, crisis center visit, mobile crisis unit intervention, arrest/incarceration, and suicide or suicide attempt) in patients under their care during a 12 month period.
NCT03158805 ↗	Saxenda® in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated)	Recruiting	Lindner Center of HOPE	Phase 2	2017-04-26	Taken together these data support the hypothesis that liraglutide 3.0 mg sc injection will reduce body weight and improve metabolic variables in obese or overweight patients with BP without worsening psychiatric symptoms. The investigators predict that liraglutide 3.0 mg sc injection will display greater efficacy as compared to placebo in decreasing body weight in patients with BP who are obese or overweight. To prove this hypothesis, investigators will conduct a single-center, randomized, placebo-controlled, double-blind, parallel-group, 2-arm clinical trial of liraglutide 3.0 mg sc injection in 60 obese or overweight outpatients with stable BP. The investigators have chosen BP rather than another SMI because it is the most common SMI (more common than schizophrenia or schizoaffective disorder) and has a particularly strong association with obesity.

Clinical Trial Conditions for thiothixene hydrochloride

Condition Name

Condition Name for thiothixene hydrochloride
Intervention	Trials
Schizophrenia	3
Bipolar Disorder	2
Psychotic Disorders	1
Schizoaffective Disorder	1

Condition MeSH

Condition MeSH for thiothixene hydrochloride
Intervention	Trials
Schizophrenia	3
Bipolar Disorder	2
Disease	2
Psychotic Disorders	1

Clinical Trial Locations for thiothixene hydrochloride

Trials by Country

Trials by Country for thiothixene hydrochloride
Location	Trials
United States	24
Canada	1

Trials by US State

Trials by US State for thiothixene hydrochloride
Location	Trials
Ohio	2
Illinois	1
Georgia	1
Florida	1
Connecticut	1

Clinical Trial Progress for thiothixene hydrochloride

Clinical Trial Phase

Clinical Trial Phase for thiothixene hydrochloride
Clinical Trial Phase	Trials
Phase 2	1
N/A	1

Clinical Trial Status

Clinical Trial Status for thiothixene hydrochloride
Clinical Trial Phase	Trials
Completed	3
Recruiting	1

Clinical Trial Sponsors for thiothixene hydrochloride

Sponsor Name

Sponsor Name for thiothixene hydrochloride
Sponsor	Trials
University of North Carolina, Chapel Hill	1
Canadian Institutes of Health Research (CIHR)	1
Drug Safety and Effectiveness Network, Canada	1

Sponsor Type

Sponsor Type for thiothixene hydrochloride
Sponsor	Trials
Other	5
Industry	1

Thiothixene hydrochloride Market Analysis and Financial Projection

Last updated: April 28, 2026

Thiothixene Hydrochloride: Clinical Trial Update, Market Analysis, and Projection

What is thiothixene hydrochloride and what is its current clinical posture?

Thiothixene hydrochloride is an older first-generation (typical) antipsychotic administered orally. It is marketed in the U.S. and is used in the treatment of schizophrenia and other psychotic disorders. The drug’s clinical development footprint in recent years is dominated by post-approval use rather than new pivotal trials, with limited visibility of large, ongoing global Phase 2/3 programs in public registries for brand-new indications.

Clinical trial activity (what is most likely to be observed in current databases):

• Low volume of new interventional studies relative to newer atypical antipsychotics.
• Regulatory focus on label maintenance and manufacturing lifecycle activities (not late-stage efficacy expansion).
• Enabling studies (bioequivalence and formulation) when generic or dosage-form changes are pursued.

Because thiothixene is an established, off-patent product class, the dominant “trial-like” evidence stream typically shifts toward:

• Bioequivalence (BE) studies for generic entries and reformulations
• Real-world or observational evidence tied to utilization patterns
• Safety surveillance rather than new dose-response superiority programs

Are there active Phase 2/3 programs that could change the market outlook?

No evidence in the public domain indicates an active, late-stage Phase 2 or Phase 3 program that would materially reset the revenue horizon for thiothixene hydrochloride through label expansion or new indication approvals. For investment or competitive planning, that means thiothixene’s market trajectory is driven primarily by:

• continued access through generic supply,
• payer and channel preferences,
• substitution dynamics inside the typical antipsychotic and broader antipsychotic buckets,
• and pricing pressure from generic competition.

How does thiothixene’s competitive landscape affect its near-term revenues?

Thiothixene competes in a crowded psychosis-treatment environment where formularies increasingly center on second-generation antipsychotics and long-acting injectables (LAIs). Typical antipsychotics remain available, but their share is pressured by:

• clinician preference for metabolic- and side-effect profile management,
• patient adherence tools (LAIs),
• and broader payer contracting on widely used atypicals.

Direct competitive set (functional substitutes):

• Other typical antipsychotics used for schizophrenia (e.g., haloperidol, fluphenazine, chlorpromazine, perphenazine)
• Second-generation antipsychotics used for schizophrenia (e.g., risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole)
• LAI antipsychotics that reduce relapse risk and improve adherence

Even if thiothixene maintains clinical relevance for a subset of patients, its economics are shaped by generic pricing and substitution.

---

Market Analysis: How is thiothixene hydrochloride likely priced and sold?

What is the product economics model for off-patent typical antipsychotics?

Thiothixene hydrochloride is expected to follow the standard generic drug economics pattern:

• Multiple ANDA/authorized generics drive net price erosion
• Procurement contracting shifts volume toward lowest-cost or contracted SKUs
• Channel consolidation (group purchasing organizations, PBM rebates where applicable) compresses list-to-net spreads
• Low marketing differentiation means demand is sensitive to stock availability and contracted prices

Demand anchor segments:

• legacy prescribers who use thiothixene for tolerability or patient history,
• institutions with stable psychosis formularies,
• and outpatient patients who remain on a stable regimen.

How does substitution risk work in schizophrenia pharmacotherapy?

Substitution risk comes from clinical and operational factors:

• formulary preference for second-generation antipsychotics,
• LAIs for adherence-sensitive patients,
• switching driven by adverse event management or patient preference,
• and utilization management when generic atypicals are cost-competitive.

For thiothixene, substitution is less about absolute efficacy versus a newcomer and more about payer and prescriber behavior inside a broad drug class.

What are the likely demand growth constraints?

Thiothixene’s growth is constrained by:

• the lack of new trial-driven label expansions that would expand eligible populations,
• demographic and diagnosis trends that mostly benefit the broad class rather than a single off-patent molecule,
• and persistent competitive pressure from newer generics within the antipsychotic market.

---

Forecast: What is the likely market trajectory for thiothixene through 2028–2030?

Projection framework

Given the drug’s established status, absence of visible late-stage programs changing indication or dosing, and the generic market structure, the projection is best treated as a volume-stable / price-declining or volume-softening scenario.

Base-case projection mechanics (generic antipsychotic pattern):

• Unit volume: flat to modestly down due to substitution and prescriber shift
• Net price: continues to trend down slowly as contracting resets
• Revenue: reflects net price compression and any volume erosion

Revenue outlook (directional)

• Near term (next 12-24 months): stable-to-declining revenue, driven more by net price than by usage
• Mid term (2025-2027): gradual decline, unless supply stability or contracting shifts improve channel share
• Longer term (2028-2030): continued pressure, with the more likely outcome being a low-single-digit annual revenue contraction

This is a business-operations view: in off-patent antipsychotics, the molecule’s “strategy” is mostly supply reliability and contracted access, not clinical differentiation.

---

Investment-grade implications (what matters for R&D, licensing, and supply planning)

Where can upside exist despite clinical maturity?

Without new Phase 2/3 programs, upside typically comes from:

• formulation improvements that reduce substitution friction (if supported by local evidence and payer acceptance),
• supply chain resilience that prevents stockouts (lost share in generic markets can be hard to regain),
• contract wins at PBMs/GPOs where lowest net price and formulary placement drive volume.

What risks dominate downside?

• channel substitution away from older typicals toward preferred second-generation options,
• pricing resets that compress net price further,
• manufacturing capacity constraints at any supplier level,
• utilization management tightening within certain payer cohorts.

---

Key Takeaways

• Thiothixene hydrochloride is a mature, off-patent typical antipsychotic where current value is driven by generic market mechanics rather than late-stage clinical expansion.
• Public visibility suggests no material late-stage (Phase 2/3) pipeline activity that would reset the revenue trajectory through new approvals.
• Market outlook is best modeled as stable-to-declining revenues over 2025-2030, with net price compression and substitution risk being the principal drivers.
• Any upside is likely operational (supply, contracting, formulation access), not clinical differentiation.

---

FAQs

1) Why is thiothixene’s market outlook mostly price and contracting driven?

Because it is an established generic molecule without visible late-stage development likely to expand indications or dosing guidelines that materially shift demand.

2) What clinical evidence would most change thiothixene’s demand?

A credible label expansion or guideline movement supported by new controlled clinical efficacy and safety evidence. Without that, utilization behaves like typical antipsychotic substitution dynamics.

3) How do PBMs and formularies typically influence thiothixene?

They steer volume toward contracted lowest net cost options and preferred antipsychotics, often compressing older typicals as second-generation generics remain price-competitive.

4) What is the most important near-term operational factor for thiothixene revenue?

Supply reliability and ability to maintain contracted formulary position during procurement cycles.

5) Is the market forecast likely to show growth?

Base-case expectations are gradual decline or stability, not high growth, due to substitution toward broader antipsychotic choices and continued generic price pressure.

---

References (APA)

[1] U.S. Food and Drug Administration. (n.d.). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
[2] ClinicalTrials.gov. (n.d.). Thiothixene hydrochloride studies. https://clinicaltrials.gov/
[3] National Library of Medicine. (n.d.). MedlinePlus: Thiothixene. https://medlineplus.gov/